Background. Sjogren’s syndrome (SS) is among the most frequent autoimmune diseases and one of its most severe extraglandular manifestations is peripheral neuropathy. There is no consensus about peripheral neuropathy treatment in SS. Our aim is to identify studies proving the efficiency of immunosuppressive treatment on peripheral neuropathies in SS.
Methods. The search was conducted on the PubMed (MEDLINE) database. Studies with patients diagnosed with SS and peripheral neuropathy were included. Treatment with one of the following was among inclusion criteria: glucocorticoids (GC), rituximab (RTX), azathioprine (AZA), mycophenolic acid (MMF), cyclophosphamide (CP), methotrexate (MTX), plasmapheresis or iv immunoglobulins (IV IG).
Results. A total of 116 results were found and abstracts were examined. 103 papers were excluded, and the remaining 13 papers were analyzed. They were 3 case series and 10 case reports, retrospective, totalizing 62 patients of which 22 (35.5%) received IV IG, 8 (13%) received RTX, 7 (11%) CP, and 5 (8%) received only GC. Drug associations containing corticosteroids were frequent. Of those 22 treated with IV IG, 18 patients improved (82%), and 4 stabilized (18%).
IV IG was useful in sensory, motor and sensorimotor neuropathies. CP had good results in mononeuritis multiplex, while autonomic neuropathies responded well to GC or RTX. AZA, RTX, MTX, MMF or plasmapheresis were not used alone. Follow-up periods were heterogenous and the evaluation of the neuropathy was not systematic.
Conclusion. There is only low level evidence (retrospective case reports and case series). In most cases, IV IG treatment in patients with peripheral neuropathies and SS resulted in clinical improvement, while other therapies, such as RTX, corticosteroids and CP proved to be useful in a handful of cases.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. FISHER B.A., BROWN R.M., BOWMAN S.J., BARONE F. A review of salivary gland histopathology in primary Sjögren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015; 74:1645–50.
2. CHERIF E., BOUKHRIS I., HAJJI R., HASSINE LB., AZZABI S., KECHAOU I. et al. Extra-glandular manifestations of primary Sjögren’s syndrome. Eur J Intern Med. 2013; 24:e119.
3. ATTWOOD W., POSER CM. Neurologic complications of Sjogren’s syndrome. Neurology. 1961; 11:1034–41.
4. PAVLAKIS P.P., ALEXOPOULOS H., KOSMIDIS M.L., MAMALI I., MOUTSOPOULOS H.M., TZIOUFAS A.G. et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012; 39:27–33.
5. MARGARETTEN M. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018; 56:99–105.
6. DELALANDE S., DE SEZE J., FAUCHAIS A.-L., HACHULLA E., STOJKOVIC T., FERRIBY D. et al. Neurologic manifestations in primary Sjögren syndrome. Medicine (Baltimore). 2004; 83:280–91.
7. MOROZUMI S., KAWAGASHIRA Y., IIJIMA M., KOIKE H., HATTORI N., KATSUNO M. et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren’s syndrome. J Neurol Sci. 2009; 279:57–61.
8. LEVY Y., UZIEL Y., ZANDMAN G.G., AMITAL H., SHERER Y., LANGEVITZ P. et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 62:1221–3.
9. MOCHIZUKI H., KAMAKURA K., MASAKI T., HIRATA A., NAKAMURA R., MOTOYOSHI K. Motor dominant neuropathy in Sjoegren’s syndrome: Report of two cases. Intern Med. 2008; 41:142–6.
10. FONT J., RAMOS-CASALS M., DE LA RED G., POU A., CASANOVA A., GARCIA-CARRASCO M. et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003; 30:1552–7.
11. RIST S., SELLAM J., HACHULLA E., SORDET C., PUECHAL X., HATRON P. et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: A national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011; 63:1339–44.
12. PERTOVAARA M., KORPELA M. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy. Clin Exp Rheumatol. 2012; 30:808.
13. MEKINIAN A., RAVAUD P., HATRON P.Y., LARROCHE C., LEONE J., GOMBERT B. et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012; 71:84–7.
14. MIN J.K., PARK K.S., YU W.J., LEE Y.S., PARK S.M., PARK S.H. et al. Systemic mononuclear inflammatory vasculopathy associated with Sjögren’s syndrome in a patient with primary biliary cirrhosis. Korean J Intern Med. 2000; 15:89–92.
15. SHIMOYAMA M., OHTAHARA A., OKAMURA T., WATANABE M., FUJIMOTO Y., TESHIMA S. et al. Isolated autonomic cardiovascular neuropathy in a patient with primary Sjögren syndrome: a case of successful treatment with glucocorticoid. Am J Med Sci. 2002; 324:170–2.
16. DUPOND J.L., GIL H., DE WAZIERES B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjögren’s syndrome. Am J Med. 1999; 106:125.
17. PASCUAL J., CID C., BERCIANO J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjögren’s syndrome. Neurology. 1998; 51:650–1.
18. KIZAWA M., MORI K., IIJIMA M., KOIKE H., HATTORI N., SOBUE G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006; 77:967–9.
19. MOLINA J.A., BENITO-LEÓN J., BERMEJO F., JIMÉNEZ-JIMÉNEZ F.J., OLIVÁN J. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 1996; 60:699.
20. TAKAHASHI Y., TAKATA T., HOSHINO M., SAKURAI M., KANAZAWA I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology. 2003; 60:503–5.
21. MORI K., IIJIMA M., KOIKE H., HATTORI N., TANAKA F., WATANABE H. et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005; 128:2518–34.
22. GORSON K.C., NATARAJAN N., ROPPER A.H., WEINSTEIN R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve. 2007; 35:66–9.
23. BOTEZ S.A., HERRMANN D.N. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren’s syndrome after Rituximab therapy. J Clin Neuromuscul Dis. 2010; 11:127–31.
24. MEIJER J.M., MEINERS P.M., VISSINK A., SPIJKERVET F.K.L., ABDULAHAD W., KAMMINGA N. et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62:960–8.
25. VOULGARELIS M., GIANNOULI S., TZIOUFAS A.G., MOUTSOPOULOS H.M. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006; 65:1033–7.
26. MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., GROUP T.P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009; 6:e1000097.
27. WAKASUGI D., KATO T., GONO T., ITO E., NODERA H., KAWAGUCHI Y. et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren’s syndrome. Mod Rheumatol. 2009; 19:437–40.